Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Assets (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Current Assets for 16 consecutive years, with $894.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 43.36% year-over-year to $894.0 million, compared with a TTM value of $894.0 million through Dec 2025, up 43.36%, and an annual FY2025 reading of $894.0 million, up 43.36% over the prior year.
  • Current Assets was $894.0 million for Q4 2025 at Catalyst Pharmaceuticals, up from $852.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $894.0 million in Q4 2025 and bottomed at $161.5 million in Q1 2021.
  • Average Current Assets over 5 years is $433.3 million, with a median of $320.8 million recorded in 2022.
  • The sharpest move saw Current Assets crashed 31.63% in 2023, then surged 184.33% in 2024.
  • Year by year, Current Assets stood at $210.1 million in 2021, then soared by 52.69% to $320.8 million in 2022, then tumbled by 31.63% to $219.3 million in 2023, then soared by 184.33% to $623.6 million in 2024, then skyrocketed by 43.36% to $894.0 million in 2025.
  • Business Quant data shows Current Assets for CPRX at $894.0 million in Q4 2025, $852.5 million in Q3 2025, and $758.7 million in Q2 2025.